Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma

Abstract

Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is an aberrant fusion gene product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL). It has been shown that NPM-ALK binds to and activates signal transducer and activator of transcription 3 (STAT3) in vitro, and that STAT3 is constitutively active in ALK+ ALCL cell lines and tumors. In view of the oncogenic potential of STAT3, we further examined its biological significance in ALCL using two ALK+ ALCL cell lines (Karpas 299 and SU-DHL-1) and an adenoviral vector that carries dominant-negative STAT3 (AdSTAT3DN). Infection by AdSTAT3DN led to the expression of STAT3DN in both ALK+ ALCL cell lines at a similar efficiency. Subcellular fractionation studies showed that a significant proportion of the expressed STAT3DN protein translocated to the nucleus, despite the fact that STAT3DN has a mutation at residue 705tyrosine → phenylalanine, a site that is believed to be crucial for STAT3 activation and nuclear translocation. Introduction of STAT3DN induced apoptosis and G1 cell cycle arrest. Western blot studies showed that expression of STAT3DN resulted in caspase-3 cleavage, downregulation of Bcl-2, Bcl-xL, cyclin D3, survivin, Mcl-1, c-Myc and suppressor of cytokine signaling 3. These results support the concept that STAT3 activation is pathogenetically important in ALCL cells by deregulating the expression of multiple target proteins that are involved in the control of apoptosis and cell cycle progression.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Alexander WS, Starr R, Metcalf D, Nicholson SE, Farley A, Elefanty AG, Brysha M, Kile BT, Richardson R, Baca M, Zhang JG, Willson TA, Viney EM, Sprigg NS, Rakar S, Corbin J, Mifsud S, DiRago L, Cary D, Nicola NA and Hilton DJ . (1999). J. Leukocyte Biol., 66, 588–592.

  • Altieri DC . (2001). Trends Mol. Med., 12, 542–547.

  • Aoki Y, Feldman GM and Tosato G . (2002). Blood, 101, 1535–1542.

  • Bai RY, Dieter P, Peschel C, Morris SW and Duyster J . (1998). Mol. Cell. Biol., 18, 6951–6961.

  • Bischof D, Pulford K, Mason DY and Morris SW . (1997). Mol. Cell. Biol., 17, 2313–2325.

  • Borer RA, Lehner CF, Eppenberger HM and Nigg EA . (1989). Cell, 56, 379–390.

  • Bowman T, Garcia R, Turkson J and Jove R . (2002). Oncogene, 19, 2474–2488.

  • Brender C, Nielsen M, Kaltoft K, Mikkelsen G, Zhang Q, Wasik M, Billestrup N and Odum N . (2001). Blood, 97, 1056–1062.

  • Bromberg J and Darnell Jr JE . (2000). Oncogene, 19, 2468–2473.

  • Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell Jr JE . (1999). Cell, 98, 295–303.

  • Buttner R, Mora LB and Jove R . (2002). Clin. Cancer Res., 8, 945–954.

  • Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna JL, Nunez G, Dalton WS and Jove R . (1999). Immunity, 10, 105–115.

  • Chai SK, Nichols GL and Rothman P . (1997). J. Immunol., 15, 4720–4728.

  • Darnell JE . (1997). Science, 277, 1630–1635.

  • Delsol G, Ralfkiaer E, Stein H, Wright D and Jaffe E . (2001). Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues: World Health Organization Classification of Tumours, Jaffe E, Harris N, Stein H and Vardiman J (eds). IARC Press: Lyon, France, pp. 230–235.

    Google Scholar 

  • Duyster J, Bai RY and Morris SW . (2001). Oncogene, 20, 5623–5637.

  • Epling-Burnette PK, Liu JH, Catlett-Falcone R, Turkson J, Oshiro M, Kothapalli R, Li Y, Wang JM, Yang-Yen HF, Karras J, Jove R and Loughran Jr TP . (2001). J. Clin. Invest., 107, 351–362.

  • Epstein AL and Kaplan HS . (1979). Cancer Res., 39, 1748–1759.

  • Fagerlund R, Melen K, Kinnunen L and Julkunen I . (2002). J. Biol. Chem., 277, 30072–30078.

  • Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci PG, Flenghi L, Martelli MF and Santucci A . (1999). Blood, 93, 2697–2706.

  • Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP and Jove R . (1997). Cell Growth Differ., 8, 1267–1276.

  • Gascoyne RD, Aoun P, Wu D, Chhanabhai M, Skinnider BF, Greiner TC, Morris SW, Connors JM, Vose JM, Viswanatha DS, Coldman A and Weisenburger DD . (1999). Blood, 93, 3913–3921.

  • Gouilleux-Gruart V, Gouilleux F, Desaint C, Claisse JF, Capiod JC, Delobel J, Weber-Nordt R, Dusanter-Fourt I, Dreyfus F, Groner B and Prin L . (1996). Blood, 87, 1692–1697.

  • Grandis JR, Drenning SD, Chakraborty A, Zhou MY, Zeng Q, Pitt AS and Tweardy DJ . (1998). J. Clin. Invest., 102, 1385–1392.

  • Hilton DJ . (1999). Cell. Mol. Life Sci., 55, 1568–1577.

  • Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T, Mori S, Ratzkin B and Yamamoto T . (1997). Oncogene, 14, 439–449.

  • Kube D, Holtick U, Vockerodt M, Ahmadi T, Haier B, Behrmann I, Heinrich PC, Diehl V and Tesch H . (2001). Blood, 98, 762–770.

  • Kunisada K, Tone E, Fujio Y, Matsui H, Yamauchi-Takihara K and Kishimoto T . (1998). Circulation, 98, 346–352.

  • Mahboubi K, Li F, Plescia J, Kirkiles-Smith NC, Mesri M, Du Y, Carroll JM, Elias JA, Altieri DC and Pober JS . (2001). Lab. Invest., 81, 327–334.

  • Matsui T, Kinoshita T, Hirano T, Yokota T and Miyajima A . (2002). J. Biol. Chem., 277, 36167–36173.

  • Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J and Jove R . (2002). Cancer Res., 62, 6659–6666.

  • Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL and Look AT . (1994). Science, 263, 1281–1284.

  • Morris SW, Naeve C, Mathew P, James PL, Kirstein MN, Cui X and Witte DP . (1997). Oncogene, 14, 2175–2188.

  • Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, Nishimoto N, Kajita T, Taga T, Yoshizaki K, Akira S and Kishimoto T . (1997). Nature, 387, 924–929.

  • Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T and Yamauchi-Takihara K . (2001). Circulation, 104, 979–981.

  • Nielsen M, Kæstel CG, Eriksen KW, Woetmann A, Stokkedal T, Kaltoft K, Geisler C, Röpke C and Ødum N . (1999). Leukemia, 13, 735–738.

  • Niu G, Bowman T, Huang M, Shivers S, Reintgen D, Daud A, Chang A, Kraker A, Jove R and Yu H . (2002). Oncogene, 21, 7001–7010.

  • Osugi T, Oshima Y, Fujio Y, Funamoto M, Yamashita A, Negoro S, Kunisada K, Izumi M, Nakaoka Y, Hirota H, Okabe M, Yamauchi-Takihara K, Kawase I and Kishimoto T . (2002). J. Biol. Chem., 277, 6676–6681.

  • Rassidakis GZ, Lai R, McDonnell TJ, Cabanillas F, Sarris AH and Medeiros LJ . (2002). Am. J. Pathol., 160, 2309–2310 (letter).

  • Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, Kinjyo I, Sasaki M, Johnston JA and Yoshimura A . (1999). Genes Cells, 4, 339–351.

  • Schlette EJ, Medeiros LJ, Goy A, Lai R and Rassidakis GZ . (2004). J. Clin. Oncol., in press.

  • Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA and Skorski T . (2001). Cancer Res., 64, 2194–2199.

  • Stein H, Mason DY, Gerdes J, O’Connor N, Waincoat J, Pallesen G, Gatter K, Falini B, Delsol G and Lemke H . (1985). Blood, 66, 848–858.

  • Turkson J and Jove R . (2000). Oncogene, 19, 6613–6626.

  • Wood GS, Hardman DL, Boni R, Dummer R, Kim YH, Smoller BR, Takeshita M, Kikuchi M and Burg G . (1996). Blood, 88, 1765–1770.

  • Zamo A, Chiarle R, Piva R, Howes J, Fan Y, Chilosi M, Levy DE and Inghirami G . (2002). Oncogene, 21, 1038–1047.

  • Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, Morris S, Skorski T and Wasik MA . (2002). J. Immunol., 168, 466–474.

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Hesham M Amin or Raymond Lai.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Amin, H., McDonnell, T., Ma, Y. et al. Selective inhibition of STAT3 induces apoptosis and G1 cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23, 5426–5434 (2004). https://doi.org/10.1038/sj.onc.1207703

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1207703

Keywords

This article is cited by

Search

Quick links